NCT01385592

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 30 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the efficacy and safety of AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)

Conditions

• Dyskinesias
• Parkinson Disease
• Movement Disorders
• Parkinsonian Disorders

Interventions

Type	Name	Description
DRUG	AFQ056
DRUG	Placebo

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2011-06-30
• Last updated: 2020-12-23

Locations

28 sites across 7 countries: United States, Canada, France, Germany, Hungary, Italy, Spain